Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pacritinib with Sirolimus and Tacrolimus for GVHD Prevention
NCT02891603Phase 2Completed
- Sponsor
- Moffitt Cancer Center
- Start
- Jun 2017
- Primary completion
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of pacritinib in graft-versus-host disease (GVHD) (3 arms), sponsored by Moffitt Cancer Center. Primary endpoint: STAT Activity up to 21 days. Started Jun 2017; status: completed.
02
Drugs
pacritinib
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT02891603.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02891603.